Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema

References

• Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909
   PubMed Web of Science ®Google Scholar
• ETDRSR Group. Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified airlie house classification. ETDRS report number 10. early treatment diabetic retinopathy study research group. Ophthalmology. 1991;98(5 Suppl):786–806. doi:10.1016/S0161-6420(13)38012-9
   Web of Science ®Google Scholar
• Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1–32. doi:10.1016/j.survophthal.2008.10.001
   PubMed Web of Science ®Google Scholar
• Schwartz SG, Flynn HW Jr, Scott IU. Intravitreal corticosteroids in the management of diabetic macular edema. Curr Ophthalmol Rep. 2013;1(3):144–149. doi:10.1007/s40135-013-0015-3
   Google Scholar
• Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98(9):2018–2026. doi:10.1172/JCI119006
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12):1450–1452. doi:10.1096/fj.03-1476fje
   PubMed Web of Science ®Google Scholar
• Vujosevic S, Bini S, Midena G, Berton M, Pilotto E, Midena E. Hyperreflective intraretinal spots in diabetics without and with nonproliferative diabetic retinopathy: an in vivo study using spectral domain OCT. J Diabetes Res. 2013;2013:491835. doi:10.1155/2013/491835
   PubMed Web of Science ®Google Scholar
• Framme C, Schweizer P, Imesch M, Wolf S, Wolf-Schnurrbusch U. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2012;53(9):5814–5818. doi:10.1167/iovs.12-9950
   PubMed Web of Science ®Google Scholar
• De Benedetto U, Sacconi R, Pierro L, Lattanzio R, Bandello F. Optical coherence tomographic hyperreflective foci in early stages of diabetic retinopathy. Retina. 2015;35(3):449–453. doi:10.1097/IAE.0000000000000336
   Web of Science ®Google Scholar
• Coscas G, De Benedetto U, Coscas F, et al. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica. 2013;229(1):32–37. doi:10.1159/000342159
   PubMed Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133(1):70–77. doi:10.1016/S0002-9394(01)01269-7
   PubMed Web of Science ®Google Scholar
• Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73–79. doi:10.1016/j.ophtha.2008.09.037
   PubMed Web of Science ®Google Scholar
• Ramezani A, Ahmadieh H, Tabatabaei H. Intravitreal triamcinolone reinjection for refractory diabetic macular edema. Korean J Ophthalmol. 2006;20(3):156–161. doi:10.3341/kjo.2006.20.3.156
   Google Scholar
• Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113(9):1533–1538. doi:10.1016/j.ophtha.2006.02.065
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem. 2002;80(4):667–677. doi:10.1046/j.0022-3042.2001.00740.x
   PubMed Web of Science ®Google Scholar
• Ascaso FJ, Huerva V, Grzybowski A. The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. Mediators Inflamm. 2014;2014:432685. doi:10.1155/2014/432685
   PubMed Web of Science ®Google Scholar
• Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005;80(2):249–258. doi:10.1016/j.exer.2004.09.013
   PubMed Web of Science ®Google Scholar
• Bucolo C, Gozzo L, Longo L, Mansueto S, Vitale DC, Drago F. Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. J Pharmacol Sci. 2018;138(4):219–232. doi:10.1016/j.jphs.2018.11.001
   PubMed Web of Science ®Google Scholar
• Gerendas BS, Prager S, Deak G, et al. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema. Br J Ophthalmol. 2018;102(2):195–203. doi:10.1136/bjophthalmol-2017-310483
   PubMed Web of Science ®Google Scholar
• Guthoff R, Schrader W, Hennemann K, Meigen T, Gobel W. Prognostic factors for visual outcome after intravitreal drug therapy for chronic diabetic macular oedema. Klin Monbl Augenheilkd. 2011;228(5):468–472. doi:10.1055/s-0029-1245487
   Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two Phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022. doi:10.1016/j.ophtha.2013.02.034
   PubMed Web of Science ®Google Scholar
• Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473–2481. doi:10.1016/j.ophtha.2014.07.002
   PubMed Web of Science ®Google Scholar
• Pareja-Rios A, Ruiz-de la Fuente-rodriguez P, Bonaque-Gonzalez S, Lopez-Galvez M, Lozano-Lopez V, Romero-Aroca P. Intravitreal dexamethasone implants for diabetic macular edema. Int J Ophthalmol. 2018;11(1):77–82. doi:10.18240/ijo.2018.01.14
   PubMed Web of Science ®Google Scholar
• Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343–358. doi:10.1016/j.preteyeres.2011.05.002
   PubMed Web of Science ®Google Scholar
• Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6). doi:10.3390/ijms19061816
   Web of Science ®Google Scholar
• Mirza S, Hossain M, Mathews C, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of mexican americans: a cross-sectional study. Cytokine. 2012;57(1):136–142. doi:10.1016/j.cyto.2011.09.029
   PubMed Web of Science ®Google Scholar
• Niu S, Yu C, Chen Q, et al. Multimodality analysis of hyper-reflective foci and hard exudates in patients with diabetic retinopathy. Sci Rep. 2017;7(1):1568. doi:10.1038/s41598-017-01733-0
   Web of Science ®Google Scholar
• Lammer J, Bolz M, Baumann B, et al. Detection and analysis of hard exudates by polarization-sensitive optical coherence tomography in patients with diabetic maculopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1564–1571. doi:10.1167/iovs.13-13539
   Web of Science ®Google Scholar
• Mehta H, Gillies M, Fraser-Bell S. Perspective on the role of ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema. Ther Adv Chronic Dis. 2015;6(5):234–245. doi:10.1177/2040622315590319
   Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024
   PubMed Web of Science ®Google Scholar
• Cevik SG, Yilmaz S, Cevik MT, Akalp FD, Avci R. Comparison of the effect of intravitreal dexamethasone implant in vitrectomized and nonvitrectomized eyes for the treatment of diabetic macular edema. J Ophthalmol. 2018;2018:1757494.
   PubMed Web of Science ®Google Scholar